In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OUTLOOK 2021

Annual industry ranking and forecast

Numbers Crunched: Reviewing Biopharma's FY 2019 Performance

Executive Summary

The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?

You may also be interested in...



Pfizer Holds Number One Spot And Takeda Breaks The Top 10

Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future. 

Deals Shaping The Medical Industry, April 2021

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2021. Data provided by Biomedtracker

BMS: Retaining Top Talent Through An Acquisition And A Pandemic

Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window. 

Topics

UsernamePublicRestriction

Register

IV124667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel